|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.10 EUR | 0.00% |
|
-10.56% | +8.05% |
| Jun. 29 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| Jun. 16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
| Market Cap | 2.06B 1.81B 1.69B 1.55B 2.9B 197B 2.97B 20.01B 7.82B 97.51B 7.72B 7.56B 337B | P/E 2026 * |
-8.16x | P/E 2027 * | -9.74x |
|---|---|---|---|---|---|
| Enterprise Value | 1.56B 1.37B 1.28B 1.18B 2.2B 150B 2.26B 15.21B 5.95B 74.12B 5.87B 5.74B 256B | EV / Sales 2026 * |
3.49x | EV / Sales 2027 * | 2.84x |
| Free-Float |
95.17% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Zai Lab Limited
| 1 week | -10.56% | ||
| Current month | -2.42% | ||
| 1 month | +1.26% | ||
| 3 months | -10.06% | ||
| 6 months | +12.59% | ||
| Current year | +8.05% |
| 1 week | 16.1 |  | 18 |
| 1 month | 15.9 | | 18.1 |
| 3 years | 12.8 | | 38.8 |
| 5 years | 12.8 | | 132 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ying Du
CEO | Chief Executive Officer | 61 | 2014-03-31 |
Ya jing Chen
DFI | Director of Finance/CFO | 58 | 2023-07-06 |
Rafael Amado
PSD | President | 62 | 2022-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Ying Du
CHM | Chairman | 61 | 2014-03-31 |
John Diekman
BRD | Director/Board Member | 83 | 2016-12-31 |
Peter Wirth
BRD | Director/Board Member | 75 | 2016-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -10.56% | -54.00% | -43.71% | 2.06B | |
| +0.03% | +6.79% | +24.59% | -6.79% | 70.75B | |
| +0.28% | +3.12% | +35.58% | +214.73% | 54.35B | |
| -4.52% | +47.90% | +47.90% | +47.90% | 47.19B | |
| -0.59% | +9.81% | -53.12% | -52.67% | 42.48B | |
| +1.76% | +5.81% | +63.59% | -21.11% | 30.91B | |
| -2.18% | +9.77% | +64.26% | +101.46% | 25.76B | |
| -2.36% | -6.16% | +66.84% | -54.08% | 21.62B | |
| -2.90% | -4.12% | -11.33% | +152.31% | 19.91B | |
| -2.35% | +1.06% | +80.35% | +142.71% | 16.33B | |
| Average | -1.42% | +3.89% | +26.47% | +48.07% | 36.59B | |
| Weighted average by Cap. | -1.13% | +5.09% | +29.33% | +52.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 448M 393M 367M 337M 631M 42.88B 646M 4.35B 1.7B 21.22B 1.68B 1.64B 73.35B | 595M 522M 488M 448M 838M 56.95B 858M 5.78B 2.26B 28.18B 2.23B 2.18B 97.43B |
| Net income | -244M -215M -200M -184M -344M -23.39B -352M -2.37B -929M -11.57B -917M -897M -40B | -159M -140M -130M -120M -224M -15.22B -229M -1.55B -604M -7.53B -596M -583M -26.03B |
| Net Debt | -493M -434M -405M -371M -695M -47.27B -713M -4.8B -1.88B -23.39B -1.85B -1.81B -80.86B | -371M -326M -305M -280M -523M -35.57B -536M -3.61B -1.41B -17.6B -1.39B -1.36B -60.85B |
| Date | Price | Change |
|---|---|---|
| 26-07-30 | €16.10 | 0.00% |
| 26-07-29 | €16.10 | -2.42% |
| 26-07-28 | €16.50 | +0.61% |
| 26-07-27 | €16.40 | -3.53% |
| 26-07-24 | €17.00 | -3.41% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ZLAB Stock
- 1ZL Stock
Select your edition
All financial news and data tailored to specific country editions
